2-arachidonoylglycerol

2-arachidonoylglycerol is a lipid of Glycerolipids (GL) class. 2-arachidonoylglycerol is associated with abnormalities such as Atherosclerosis, Heart Diseases, Inflammatory disorder, Colitis and Peripheral Neuropathy. The involved functions are known as Immunoreactivity, inhibitors, Stimulus, Esthesia and Signal Transduction. 2-arachidonoylglycerol often locates in Back, Presynaptic Terminals, Brain region, Blood and Body tissue. The associated genes with 2-arachidonoylglycerol are ADRBK1 gene, Homologous Gene, MGLL gene, PLA2G4A gene and peptide V. The related lipids are oleoylethanolamide, Lipopolysaccharides, Promega, stearic acid and 1-stearoyl-2-arachidonoylglycerol. The related experimental models are Knock-out.

Cross Reference

Introduction

To understand associated biological information of 2-arachidonoylglycerol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with 2-arachidonoylglycerol?

2-arachidonoylglycerol is suspected in Atherosclerosis, Heart Diseases, Sweet's Syndrome, Colitis, Dehydration, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2-arachidonoylglycerol

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Inflammation D007249 119 associated lipids
Glioma D005910 112 associated lipids
Weight Gain D015430 101 associated lipids
Brain Ischemia D002545 89 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Alzheimer Disease D000544 76 associated lipids
Stomach Ulcer D013276 75 associated lipids
Colitis D003092 69 associated lipids
Reperfusion Injury D015427 65 associated lipids
Per page 10 20 50 100 | Total 51

PubChem Associated disorders and diseases

What pathways are associated with 2-arachidonoylglycerol

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with 2-arachidonoylglycerol?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with 2-arachidonoylglycerol?

Knock-out

Knock-out are used in the study 'Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.' (Walentiny DM et al., 2015), Knock-out are used in the study 'Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12).' (Navia-Paldanius D et al., 2012) and Knock-out are used in the study 'Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid Action.' (Viader A et al., 2015).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with 2-arachidonoylglycerol

Download all related citations
Per page 10 20 50 100 | Total 1060
Authors Title Published Journal PubMed Link
Rockwell CE et al. Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2. 2006 Mol. Pharmacol. pmid:16611855
Szabo B et al. Depolarization-induced retrograde synaptic inhibition in the mouse cerebellar cortex is mediated by 2-arachidonoylglycerol. 2006 J. Physiol. (Lond.) pmid:16973696
Kasai HF et al. Studies on high-energy collision-induced dissociation of endogenous cannabinoids: 2-arachidonoylglycerol and n-arachidonoylethanolamide in FAB-mass spectrometry. 2006 Anal Sci pmid:16837740
Mechoulam R et al. Endocannabinoids, feeding and suckling--from our perspective. 2006 Int J Obes (Lond) pmid:16570101
Matias I et al. Endogenous cannabinoids in the brain and peripheral tissues: regulation of their levels and control of food intake. 2006 Int J Obes (Lond) pmid:16570107
Waku K [Endogenous cannabinoid receptor ligands--anandamide and 2-arachidonoylglycerol]. 2006 Yakugaku Zasshi pmid:16462096
Guagnini F et al. Neural contractions in colonic strips from patients with diverticular disease: role of endocannabinoids and substance P. 2006 Gut pmid:16423891
Bari M et al. New insights into endocannabinoid degradation and its therapeutic potential. 2006 Mini Rev Med Chem pmid:16515464
Gough NR Focus issue: signaling lipids. 2006 Sci. STKE pmid:16467192
Parkkari T et al. Synthesis and CB1 receptor activities of dimethylheptyl derivatives of 2-arachidonoyl glycerol (2-AG) and 2-arachidonyl glyceryl ether (2-AGE). 2006 Bioorg. Med. Chem. pmid:16403642
Avraham Y et al. Endocannabinoids affect neurological and cognitive function in thioacetamide-induced hepatic encephalopathy in mice. 2006 Neurobiol. Dis. pmid:16102970
D'Argenio G et al. Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. 2006 FASEB J. pmid:16403786
Suplita RL et al. Endocannabinoids at the spinal level regulate, but do not mediate, nonopioid stress-induced analgesia. 2006 Neuropharmacology pmid:16316669
Juan-Picó P et al. Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell. 2006 Cell Calcium pmid:16321437
Oka S et al. Suppression by WIN55212-2, a cannabinoid receptor agonist, of inflammatory reactions in mouse ear: Interference with the actions of an endogenous ligand, 2-arachidonoylglycerol. 2006 Eur. J. Pharmacol. pmid:16647054
Melis M et al. Protective activation of the endocannabinoid system during ischemia in dopamine neurons. 2006 Neurobiol. Dis. pmid:16762556
Malcher-Lopes R et al. Opposing crosstalk between leptin and glucocorticoids rapidly modulates synaptic excitation via endocannabinoid release. 2006 J. Neurosci. pmid:16775153
Kishimoto S et al. Chemotaxis of human peripheral blood eosinophils to 2-arachidonoylglycerol: comparison with other eosinophil chemoattractants. 2006 Int. Arch. Allergy Immunol. pmid:16772720
Hermann A et al. 2-Arachidonoylglycerol (2-AG) membrane transport: history and outlook. 2006 AAPS J pmid:16808043
Yoshida T et al. Localization of diacylglycerol lipase-alpha around postsynaptic spine suggests close proximity between production site of an endocannabinoid, 2-arachidonoyl-glycerol, and presynaptic cannabinoid CB1 receptor. 2006 J. Neurosci. pmid:16672646
Sugiura T et al. Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. 2006 Prog. Lipid Res. pmid:16678907
Katona I et al. Molecular composition of the endocannabinoid system at glutamatergic synapses. 2006 J. Neurosci. pmid:16723519
Shiga N et al. Elimination of 2-arachidonoylglycerol action by direct hemoperfusion through immobilized polymyxin B fibers: an experimental study in conscious guinea pigs. 2006 Ther Apher Dial pmid:17199882
McCarron RM et al. Endothelial-mediated regulation of cerebral microcirculation. 2006 J. Physiol. Pharmacol. pmid:17244945
Parrish JC and Nichols DE Serotonin 5-HT(2A) receptor activation induces 2-arachidonoylglycerol release through a phospholipase c-dependent mechanism. 2006 J. Neurochem. pmid:17010161
Kurabayashi M et al. 2-Arachidonoylglycerol increases in ischemia-reperfusion injury of the rat liver. 2005 Jan-Feb J Invest Surg pmid:15804949
van der Stelt M et al. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. 2005 FASEB J. pmid:15894565
Lambert DM and Fowler CJ The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. 2005 J. Med. Chem. pmid:16078824
Hayase T et al. Persistent anxiogenic effects of a single or repeated doses of cocaine and methamphetamine: interactions with endogenous cannabinoid receptor ligands. 2005 Behav Pharmacol pmid:16148444
Venderova K et al. Differential effects of endocannabinoids on [(3)H]-GABA uptake in the rat globus pallidus. 2005 Exp. Neurol. pmid:15899265
Gokoh M et al. 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces rapid actin polymerization in HL-60 cells differentiated into macrophage-like cells. 2005 Biochem. J. pmid:15456404
Hohmann AG et al. An endocannabinoid mechanism for stress-induced analgesia. 2005 Nature pmid:15973410
Sancho R et al. Mechanisms of HIV-1 inhibition by the lipid mediator N-arachidonoyldopamine. 2005 J. Immunol. pmid:16148147
Harada N et al. Effects of cannabinoids on colonic muscle contractility and tension in guinea pigs. 2005 J Nippon Med Sch pmid:15834207
Oka S et al. Evidence for the involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in 12-O-tetradecanoylphorbol-13-acetate-induced acute inflammation in mouse ear. 2005 J. Biol. Chem. pmid:15749716
Kishimoto S et al. Endogenous cannabinoid receptor ligand induces the migration of human natural killer cells. 2005 J. Biochem. pmid:15749836
Julien B et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. 2005 Gastroenterology pmid:15765409
Kaplan BL et al. 2-Arachidonoyl-glycerol suppresses interferon-gamma production in phorbol ester/ionomycin-activated mouse splenocytes independent of CB1 or CB2. 2005 J. Leukoc. Biol. pmid:15774549
Lauckner JE et al. The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. 2005 Proc. Natl. Acad. Sci. U.S.A. pmid:16365309
Chen J et al. Finding of endocannabinoids in human eye tissues: implications for glaucoma. 2005 Biochem. Biophys. Res. Commun. pmid:15823551
Hill MN et al. Chronic corticosterone treatment increases the endocannabinoid 2-arachidonylglycerol in the rat amygdala. 2005 Eur. J. Pharmacol. pmid:16324692
Gokoh M et al. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, enhances the adhesion of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes. 2005 FEBS Lett. pmid:16288744
Straiker A and Mackie K Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones. 2005 J. Physiol. (Lond.) pmid:16179366
Iturralde M et al. Characterization of the lipolytic pathways that mediate free fatty acid release during Fas/CD95-induced apoptosis. 2005 Apoptosis pmid:16215685
Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. 2005 Diabetes pmid:16186383
Safo PK and Regehr WG Endocannabinoids control the induction of cerebellar LTD. 2005 Neuron pmid:16301180
Alger BE Endocannabinoid identification in the brain: studies of breakdown lead to breakthrough, and there may be NO hope. 2005 Sci. STKE pmid:16278487
Maccarrone M et al. Up-regulation of the endocannabinoid system in the uterus of leptin knockout (ob/ob) mice and implications for fertility. 2005 Mol. Hum. Reprod. pmid:15563449
Rademacher DJ et al. Waterborne lead exposure affects brain endocannabinoid content in male but not female fathead minnows (Pimephales promelas). 2005 Neurotoxicology pmid:15527869
Shoemaker JL et al. Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors. 2005 J. Pharmacol. Exp. Ther. pmid:16081674
Sipe JC et al. Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: possible risk for autoimmune disorders. 2005 J. Leukoc. Biol. pmid:15845647
Jung KM et al. Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. 2005 Mol. Pharmacol. pmid:16051747
Makara JK et al. Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. 2005 Nat. Neurosci. pmid:16116451
Ligresti A et al. Endocannabinoid metabolic pathways and enzymes. 2005 Curr Drug Targets CNS Neurol Disord pmid:16375679
Secko D Analgesia through endogenous cannabinoids. 2005 CMAJ pmid:16103504
Maejima T et al. Synaptically driven endocannabinoid release requires Ca2+-assisted metabotropic glutamate receptor subtype 1 to phospholipase Cbeta4 signaling cascade in the cerebellum. 2005 J. Neurosci. pmid:16033892
Panikashvili D et al. CB1 cannabinoid receptors are involved in neuroprotection via NF-kappa B inhibition. 2005 J. Cereb. Blood Flow Metab. pmid:15729296
Gopez JJ et al. Cyclooxygenase-2-specific inhibitor improves functional outcomes, provides neuroprotection, and reduces inflammation in a rat model of traumatic brain injury. 2005 Neurosurgery pmid:15730585
Zhao Q et al. 2-Arachidonoylglycerol stimulates activator protein-1-dependent transcriptional activity and enhances epidermal growth factor-induced cell transformation in JB6 P+ cells. 2005 J. Biol. Chem. pmid:15886210
Rouzer CA and Marnett LJ Glycerylprostaglandin synthesis by resident peritoneal macrophages in response to a zymosan stimulus. 2005 J. Biol. Chem. pmid:15917246
Nithipatikom K et al. A new class of inhibitors of 2-arachidonoylglycerol hydrolysis and invasion of prostate cancer cells. 2005 Biochem. Biophys. Res. Commun. pmid:15919052
Darmani NA et al. Cisplatin increases brain 2-arachidonoylglycerol (2-AG) and concomitantly reduces intestinal 2-AG and anandamide levels in the least shrew. 2005 Neuropharmacology pmid:15921709
Kola B et al. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. 2005 J. Biol. Chem. pmid:15899896
Shoemaker JL et al. The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors. 2005 J. Pharmacol. Exp. Ther. pmid:15901805
Saario SM et al. Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes. 2005 Chem. Biol. pmid:15975510
Di S et al. Activity-dependent release and actions of endocannabinoids in the rat hypothalamic supraoptic nucleus. 2005 J. Physiol. (Lond.) pmid:16239276
Gauthier KM et al. Endothelium-derived 2-arachidonylglycerol: an intermediate in vasodilatory eicosanoid release in bovine coronary arteries. 2005 Am. J. Physiol. Heart Circ. Physiol. pmid:15528233
Gabbay E et al. Endocannabinoids and liver disease--review. 2005 Liver Int. pmid:16162147
Vandevoorde S et al. Influence of the degree of unsaturation of the acyl side chain upon the interaction of analogues of 1-arachidonoylglycerol with monoacylglycerol lipase and fatty acid amide hydrolase. 2005 Biochem. Biophys. Res. Commun. pmid:16181610
Cabranes A et al. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. 2005 Neurobiol. Dis. pmid:16242629
Ramos JA et al. Therapeutic potential of the endocannabinoid system in the brain. 2005 Mini Rev Med Chem pmid:16026307
Wagner JA et al. Coronary vasodilator effects of endogenous cannabinoids in vasopressin-preconstricted unpaced rat isolated hearts. 2005 J. Cardiovasc. Pharmacol. pmid:16116341
McPartland JM et al. Cannabimimetic effects of osteopathic manipulative treatment. 2005 J Am Osteopath Assoc pmid:16118355
Wahn H et al. The endocannabinoid arachidonyl ethanolamide (anandamide) increases pulmonary arterial pressure via cyclooxygenase-2 products in isolated rabbit lungs. 2005 Am. J. Physiol. Heart Circ. Physiol. pmid:16055511
Kim J and Alger BE Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus. 2004 Nat. Neurosci. pmid:15184902
Witting A et al. Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice. 2004 J. Neurochem. pmid:15189359
Stanke-Labesque F et al. 2-Arachidonoyl glycerol induces contraction of isolated rat aorta: role of cyclooxygenase-derived products. 2004 Cardiovasc. Res. pmid:15194472
Oka S et al. 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces the migration of EoL-1 human eosinophilic leukemia cells and human peripheral blood eosinophils. 2004 J. Leukoc. Biol. pmid:15316028
Nithipatikom K et al. 2-arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. 2004 Cancer Res. pmid:15604240
González S et al. Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence. 2004 Drug Alcohol Depend pmid:15099659
Valenti M et al. Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain. 2004 Cell. Mol. Life Sci. pmid:15095014
Kishimoto S et al. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces accelerated production of chemokines in HL-60 cells. 2004 J. Biochem. pmid:15115777
Hájos N et al. Endocannabinoid transport tightly controls 2-arachidonoyl glycerol actions in the hippocampus: effects of low temperature and the transport inhibitor AM404. 2004 Eur. J. Neurosci. pmid:15182306
Vannacci A et al. The endocannabinoid 2-arachidonylglycerol decreases the immunological activation of Guinea pig mast cells: involvement of nitric oxide and eicosanoids. 2004 J. Pharmacol. Exp. Ther. pmid:15187170
Maestroni GJ The endogenous cannabinoid 2-arachidonoyl glycerol as in vivo chemoattractant for dendritic cells and adjuvant for Th1 response to a soluble protein. 2004 FASEB J. pmid:15385435
Walter L et al. ATP induces a rapid and pronounced increase in 2-arachidonoylglycerol production by astrocytes, a response limited by monoacylglycerol lipase. 2004 J. Neurosci. pmid:15371507
Dinh TP et al. RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. 2004 Mol. Pharmacol. pmid:15272052
Malorni W et al. Morphological evidence that 2-arachidonoylglycerol is a true agonist of human platelets. 2004 Thromb. Haemost. pmid:15543349
Melis M et al. Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. 2004 J. Neurosci. pmid:15564588
Sugiura T et al. New perspectives in the studies on endocannabinoid and cannabis: 2-arachidonoylglycerol as a possible novel mediator of inflammation. 2004 J. Pharmacol. Sci. pmid:15599096
Saario SM et al. Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. 2004 Biochem. Pharmacol. pmid:15013854
Alberich Jordà M et al. The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner. 2004 Blood pmid:15039279
Witting A et al. P2X7 receptors control 2-arachidonoylglycerol production by microglial cells. 2004 Proc. Natl. Acad. Sci. U.S.A. pmid:14976257
Carrier EJ et al. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. 2004 Mol. Pharmacol. pmid:15044630
Golech SA et al. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. 2004 Brain Res. Mol. Brain Res. pmid:15548432
Mukherjee S et al. Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors. 2004 Eur. J. Pharmacol. pmid:15556131
Guo J and Ikeda SR Endocannabinoids modulate N-type calcium channels and G-protein-coupled inwardly rectifying potassium channels via CB1 cannabinoid receptors heterologously expressed in mammalian neurons. 2004 Mol. Pharmacol. pmid:14978245
Piomelli D The endogenous cannabinoid system and the treatment of marijuana dependence. 2004 Neuropharmacology pmid:15464150
Ghafouri N et al. Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol. 2004 Br. J. Pharmacol. pmid:15492019
Motobe T et al. Endogenous cannabinoids are candidates for lipid mediators of bone cement implantation syndrome. 2004 Shock pmid:14676677